GLP-1 Drugs Associated With Lower Overall Cancer Risk

Full Article URL: <a target="_blank" href="https://jamanetwork.com/journals/jama/fullarticle/2839049">https://jamanetwork.com/journals/jama/fullarticle/2839049
Textarea URL (this page): <a href="https://textarea.nl/i/eNrLKCkpKLbS189KzE3MSy0pzy_K1kvOz9XPyi8tykvMKQZL6KeV5uQkFpVkJuek6htZGFsamFgCAHYZFKk=_2025-10-14">https://textarea.nl/i/eNrLKCkpKLbS189KzE3MSy0pzy_K1kvOz9XPyi8tykvMKQZL6KeV5uQkFpVkJuek6htZGFsamFgCAHYZFKk=_2025-10-14
Source: https://jamanetwork.com/rss/site_3/67.xml
Jamanetwork.com: https://jamanetwork.com
Publication date: 2025-10-14 00:00:00
Last retrieval: 2025-10-15 06:46:12.573568

00:00 - 14 Oct 2025

Obesity is a risk factor for several forms of cancer that comprise 40% of annual cancer diagnoses in the US. New findings published in JAMA Oncology suggest that glucagon-like peptide-1 (GLP-1) receptor agonists may help protect against some of these cancer types.